AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00654784
Drug: idebenone
RxNorm normalized name: Idebenone
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: idebenone 450 mg/day (150 mg three times a day)
Trial: NCT02877355
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
Trial: NCT02738177
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation high up in the posterior fornix (misoprostol group)
Trial: NCT02738177
Drug: Isosorbide-5-mononitrate
RxNorm normalized name: Isosorbide-5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 tablets of Effox (i.e. 40 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (effox group)
Trial: NCT02738177
Drug: misoprostol and Isosorbide-5-mononitrate
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1tablets of misoprostol (i.e.200 ug) \& 1 tablets of Effox (i.e. 20 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (combination therapy group)
Trial: NCT01741753
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, 1000 mg, every morning
Trial: NCT01741753
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally, 5 mg, every morning
Trial: NCT02175771
Drug: Fp MDPI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening.
Trial: NCT02175771
Drug: FLOVENT HFA
RxNorm normalized name: Flovent HFA
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.~During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening.
Trial: NCT02175771
Drug: ADVAIR DISKUS
RxNorm normalized name: Advair Diskus
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.~During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening.
Trial: NCT02175771
Drug: albuterol/salbutamol HFA
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Trial: NCT00568880
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bortezomib 1.0-1.3mg/m2 IV
Trial: NCT00568880
Drug: hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydroxychloroquine 200 mg pill
Trial: NCT02598466
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02504268
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04215523
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin dispensing claim for any dose is exposure
Trial: NCT04215523
Drug: DPP-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP4 inhibitor dispensing claim for any dose is reference
Trial: NCT01112111
Drug: mode of gonadotropin administration
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose step-up administration Step down administration sequential administration
Trial: NCT00212706
Drug: ONO-8025 (KRP-197)
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003658
Drug: pentostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00893048
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone, 60 mg, one time at time of diagnosis
Trial: NCT01670409
Drug: PF
RxNorm normalized name: PFT
DrugBank: Bentiromide (DB00522)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
Trial: NCT00779324
Drug: Amantadine Hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg every morning and noon
Trial: NCT00307515
Drug: Fibrin Sealant 2 (FS2)
RxNorm normalized name: thrombin
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
Trial: NCT01621672
Drug: Revlimid
RxNorm normalized name: Revlimid
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/day in the morning same time each day
Trial: NCT00782405
Drug: quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XR, 150-300mg
Trial: NCT00077025
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
Trial: NCT00077025
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
Trial: NCT03507166
Drug: RC48-ADC
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg/kg IV every 2 weeks
Trial: NCT02828111
Drug: Patidegib
RxNorm normalized name: Patidegib
DrugBank: Patidegib (DB12655)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00782405
Drug: mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-45 mg
Trial: NCT01168817
Drug: BAY60-4552 plus Vardenafil
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
Trial: NCT01168817
Drug: Vardenafil
RxNorm normalized name: Vardenafil
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
Trial: NCT04117932
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
Trial: NCT01869751
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment with prucalopride for slow-transit constipation
Trial: NCT00123916
Drug: Benznidazole
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
Trial: NCT00781599
Drug: Chantix
RxNorm normalized name: Chantix
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
Trial: NCT03220191
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: palbociclib tablet formulation
Trial: NCT03220191
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rabeprazole as PPI
Trial: NCT03912857
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd
Trial: NCT05369650
Drug: Lidocaine Hydrochloride, Injectable
RxNorm normalized name: Lidocaine Hydrochloride, Injectable
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.
Trial: NCT00235976
Drug: Gantacurium Chloride for Injection (AV430A)
RxNorm normalized name: potassium chloride Powder for Oral Solution
DrugBank: Gantacurium (DB05710)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00089440
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03043664
Drug: Lanreotide
RxNorm normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Somatuline depot (lanreotide) 90 mg SQ every 3 weeks
Trial: NCT03043664
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Keytruda (pembrolizumab) 200 mg IV every 3 weeks
Trial: NCT02412930
Drug: Group Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
Trial: NCT02412930
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01985594
Drug: utrogestan
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Tablet Utrogestan 400 mg daily for 2 days
Trial: NCT01985594
Drug: Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
Trial: NCT02864082
Drug: PAT-001, 0.1%
DrugBank: AT-001 (DB15121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
Trial: NCT02864082
Drug: PAT-001, 0.2%
DrugBank: AT-001 (DB15121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
Trial: NCT02864082
Drug: Vehicle for PAT-001 0.1%
DrugBank: AT-001 (DB15121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
Trial: NCT02864082
Drug: Vehicle for PAT-001 0.2%
DrugBank: AT-001 (DB15121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
Trial: NCT03713593
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally once a day
Trial: NCT03447769
Drug: Canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg of canakinumab administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Canakinumab solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
Trial: NCT00551538
Drug: Lispro mix 75/25
RxNorm normalized name: Insulin Lispro Protamine-Insulin Lispro Mix 75/25 KwikPen
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
Trial: NCT01127178
Drug: E7016 + TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
Trial: NCT00153764
Drug: Cooper Complete One-A-Day Vitamin Supplement
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02758431
Drug: Acyline
RxNorm normalized name: Acyline
DrugBank: Acyline (DB11906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyline 300ug/kg injection will be administered on Day 0 and on day 14
Trial: NCT00551538
Drug: Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SC injection, once-daily, given in conjunction with oral antidiabetic medications.
Trial: NCT02758431
Drug: Arimidex
RxNorm normalized name: Arimidex
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arimidex Oral Tablet 1mg taken orally daily for 28 days
Trial: NCT04139317
Drug: Capmatinib
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: INC280 tablets were administered orally at 400 mg on a continuous twice daily (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle.
Trial: NCT04387084
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04387084
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02785406
Drug: suvorexant
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
Trial: NCT02785406
Drug: Placebo (for suvorexant)
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo capsules once daily at 10 PM.
Trial: NCT00991250
Drug: Temodal® or Dacarbazine Medac®
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (5-\[3,3-Dimethyl-1-triazenyl\]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver.
Trial: NCT01155947
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
Trial: NCT00511004
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparing 400 mg to 800 mg dose
Trial: NCT00511004
Drug: Diethylcarbamazine
RxNorm normalized name: Diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Providing diethylcarbamazine more frequently in combination with albendazole
Trial: NCT04642638
Drug: INO-4800
RxNorm normalized name: INO-4800
DrugBank: INO-4800 (DB15693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INO-4800 was administered ID on Day 0 and Day 28.
Trial: NCT00990652
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
Trial: NCT00990652
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
Trial: NCT00553267
Drug: fixed dose combination of telmisartan+amlodipine
RxNorm normalized name: amlodipine / telmisartan
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00553267
Drug: amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01310036
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
Trial: NCT00003269
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003269
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003269
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00775749
Drug: transdermal nicotine patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
Trial: NCT02722746
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
Trial: NCT00736866
Drug: Acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
Trial: NCT02997358
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150 μg/m²/day s.c From day 3 to day 9
Trial: NCT04580394
Drug: AD109
RxNorm normalized name: Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration before bed
Trial: NCT04580394
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration before bed
Trial: NCT04580394
Drug: R-oxybutynin
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration before bed
Trial: NCT02040883
Drug: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
Trial: NCT02040883
Drug: Tandospirone
RxNorm normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandospirone，30mg per day
Trial: NCT00668200
Drug: Reclast (ZOL446, zoledronic acid)
RxNorm normalized name: Reclast
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mg i.v. annually (real-life, physician prescribed)